Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Psoriatic Arthritis FocusRheum

kenary820 / shutterstock.com

Psoriatic arthritis (PsA) is distinguished from other forms of inflammatory arthritis by unique pathophysiology and manifestations. In this resource center, you’ll find Dr. David’s Pisetsky’s picks for the top research in psoriatic arthritis presented at ACR Convergence 2024 and our summary of the most recent ACR treatment guideline, as well as a collection of important research reviews, case reports and clinical articles on advances in the diagnosis and management of PsA.

FEATURED ARTICLE: Top Research in Psoriatic Arthritis Presented at ACR Convergence 2024, with commentary by founding editor and rheumatologist David S. Pisetsky, MD, PhD

ACR Convergence 2024

Top Research in Psoriatic Arthritis Presented at ACR Convergence 2024

Editor’s note: What research on psoriatic arthritis (PsA) presented at ACR Convergence 2024 has the greatest potential for a positive impact on clinical care, treatment options or serve as the basis for future research? That’s the question The Rheumatologist asked David S. Pisetsky, MD, PhD—our founding editor—to consider. Dr. Pisetsky, a professor of medicine and immunology…

Should We Manage Men & Women Differently?

Experts address how sex differences affect the clinical presentation, diagnosis, response to therapy and experience of illness for patients with PsA.

Advancements in Imaging

Experts shared insights into their work on building consensus for the use of musculoskeletal ultrasound for the diagnosis and management of RA and PsA.

The Management of Psoriatic Arthritis: A Review

WASHINGTON, D.C.—As of November 2024, there are 16 biologic disease-modifying anti-rheumatic drugs (bDMARDs) that are FDA approved for the treatment of psoriatic arthritis (PsA). Incredible news, right? But as my fellowship program director used to say, “There’s no free lunch.” This buffet of options is excellent for our patients, but poses challenges to the practicing…

Young Adults with Psoriatic Disease at Risk of Early Cardiovascular Disease

Background/Purpose Psoriasis and psoriatic arthritis (PsA) are closely linked inflammatory conditions that can affect both children and adults. In children, these diseases are associated with traditional cardiovascular disease risk factors and subclinical atherosclerosis. In older adults, systemic inflammation from psoriasis and PsA accelerates atherosclerosis, and these conditions are independent risk factors for severe cardiovascular disease…

New Guidance Proposed for Ultrasound in Psoriatic & Rheumatoid Arthritis

The ACR places a high priority on developing relevant, practical guidance for the rheumatology community. A current ACR project on musculoskeletal ultrasound (MSUS) will be discussed in the ACR Convergence 2024 session, Proposed ACR Guidance for Use of Musculoskeletal Ultrasound in Rheumatoid and Psoriatic Arthritis, on Saturday, Nov. 16. In the session, Veena K. Ranganath,…

Sex Matters in PsA

In patients with psoriatic arthritis (PsA), their sex matters. In the session Sex Differences in Psoriatic Arthritis, Laura Coates, MD, PhD, of the University of Oxford, and Lihi Eder, MD, PhD, of the University of Toronto, will discuss sex-related differences in clinical features, disease course, treatment response and pain perception in patients with PsA. The…

Research in Psoriatic Arthritis Most Likely to Make a Difference to Clinical Care

What research on psoriatic arthritis to be presented at ACR Convergence 2024 has the greatest potential for a positive impact on clinical care, treatment options or serve as the basis for future research? That’s the question The Rheumatologist asked David S. Pisetsky, MD, PhD—our founding editor—to consider. With thousands of research abstracts to be presented…

Psoriatic Arthritis, a Management Review

As part of the Review Course on Friday Nov. 15 at ACR Convergence 2024, Ana-Maria Orbai, MD, MHS, associate professor of medicine and director of the Psoriatic Arthritis Program at the Johns Hopkins School of Medicine, will present a session reviewing the management of psoriatic arthritis. Dr. Orbai earned her medical degree from the Iuliu…

News, Research, Case Reports, Reviews

What Clinical Factors Affect Length of Transition to Psoriatic Arthritis in Patients with Psoriasis?

Objective We aimed to identify clinical and demographic features associated with the interval between the appearance of psoriasis and the onset of psoriatic arthritis (PsA). Methods We identified patients with psoriasis and PsA diagnoses from our tertiary care psoriatic disease biorepository: a longitudinal, real-world database including clinical information and patient-reported outcomes. We used a multivariable,…

ACR on Air: A Deep Dive into Psoriatic Arthritis

Hosted by Jonathan S. Hausmann, MD, a pediatric and adult rheumatologist at Boston Children’s Hospital and Beth Israel Deaconess Medical Center, and an instructor in medicine at Harvard Medical School, ACR on Air debuted in 2019. In this episode, ACR Master (2016) Philip J. Mease, MD, joins Dr. Hausmann for a deep dive into psoriatic…

Skin & Joints: Experts Discuss Advances in PsA

SAN DIEGO—The understanding of the microenvironment in which immune cells interact with stromal cells in the synovium of psoriatic arthritis (PsA) and rheumatoid arthritis (RA) is deepening, potentially giving clues for treatments. As this understanding improves, so does the appreciation for its astounding complexity, an expert said here in a session at ACR Convergence, which…

The Heterogeneity of Psoriatic Arthritis

SAN DIEGO—Differences between psoriatic arthritis and rheumatoid arthritis highlight the need for the development of imaging modalities, laboratory tests and other biomarkers that are explored and validated specifically for PsA to advance the goal of personalized or precision medicine. In this article, expert David S. Pisetsky, MD, PhD, explores the top research in psoriatic arthritis presented at ACR Convergence 2023.

Why Mental Health Screening Is Essential for Patients with Psoriatic Disease

Research suggests that patients with psoriasis and psoriatic arthritis (PsA) have a greater risk of depression, anxiety and, in some cases, substance abuse and dependence than the general population, yet symptoms often go unrecognized and untreated by medical professionals. Both psoriasis and PsA are associated with depression, with up to 30% of patients in either…

Psoriatic Arthritis Drugs at a Glance, 2023

Biosimilars have become a therapeutic turning point for many patients who are living with rheumatic illnesses. Psoriatic arthritis (PsA) is a complex, multi-faceted chronic inflammatory musculoskeletal and skin disease where the treatment has changed considerably over the past few years. Psoriatic arthritis has an impact on about 30% of people with psoriasis.1 In 2019, the…

Psoriatic Arthritis Treatment Update

About 30% of patients with psoriasis have psoriatic arthritis (PsA), a complex, multi-faceted, chronic, inflammatory musculoskeletal and skin disease for which the treatment has changed considerably over the past few years.1 Biosimilars and other new drugs have become a therapeutic turning point for many patients suffering from rheumatic illnesses, including PsA. The treatment of PsA…